PMCTPharmaCountry
    Inicio

Actualizaciones regulatorias

Novedades regulatorias de FDA, EMA, TGA y organismos globales

#antihypertensive ×

UPDATED
Actualizaciones regulatorias
11 sept 2026•1 min de lectura
FDA Approves Ohm Laboratories’ Generic Valsartan (ANDA 077492)
The FDA has granted approval for Ohm Laboratories’ generic Valsartan tablets (40‑320 mg) under application ANDA 077492.
UPDATED
Actualizaciones regulatorias
30 ago 2026•1 min de lectura
Daewoong Pharmaceutical Initiates Phase 1 Trials of Olmesartan‑Indapamide Triple Antihypertensive
Daewoong Pharma received MFDS approval for two Phase 1 studies of its olmesartan‑amlodipine‑indapamide combo (DWJ1622), assessing PK and safety in fasting (44) and fed (36) healthy adults.